西藏大学学报
西藏大學學報
서장대학학보
Journal of Tibet University
2014年
2期
36~39
,共null页
杨娟 央拉 巴桑琼达 李长山 杜宝中
楊娟 央拉 巴桑瓊達 李長山 杜寶中
양연 앙랍 파상경체 리장산 두보중
西藏拉萨 结核分支杆菌 耐药性
西藏拉薩 結覈分支桿菌 耐藥性
서장랍살 결핵분지간균 내약성
Lhasa;Mycobacterium Tuberculosis;drug resistance
目的:了解拉萨地区结核分枝杆菌对抗结核药物的耐药情况,为临床合理用药提供参考依据。方法:采用WHO推荐的比例法对分离自西藏拉萨地区肺结核患者的198株结核分枝杆菌进行4种抗结核药物(RFP、INH、SM、LVX)的药物敏感性试验。结果:198株结核分枝杆菌中耐药菌株有125株,总耐药率为63.1%(125/198),总耐多药率为29.8%(59/198),初治耐药率为55.1%(64/116),复治耐药率为75.4%(40/53),初治耐多药率为20.7%(24/116),复治耐多药率为56.7%(30/53)。对RFP、INH、SM、LVX的耐药率分别为36.3%(72/198)、41.9%(83/198)、41.4%(82/198)和7.0%(14/198)。结论:西藏拉萨地区临床结核分枝杆菌耐药情况较为严重,应加强临床结核分枝杆菌耐药性监测,指导临床用药以防控耐药菌的产生。
目的:瞭解拉薩地區結覈分枝桿菌對抗結覈藥物的耐藥情況,為臨床閤理用藥提供參攷依據。方法:採用WHO推薦的比例法對分離自西藏拉薩地區肺結覈患者的198株結覈分枝桿菌進行4種抗結覈藥物(RFP、INH、SM、LVX)的藥物敏感性試驗。結果:198株結覈分枝桿菌中耐藥菌株有125株,總耐藥率為63.1%(125/198),總耐多藥率為29.8%(59/198),初治耐藥率為55.1%(64/116),複治耐藥率為75.4%(40/53),初治耐多藥率為20.7%(24/116),複治耐多藥率為56.7%(30/53)。對RFP、INH、SM、LVX的耐藥率分彆為36.3%(72/198)、41.9%(83/198)、41.4%(82/198)和7.0%(14/198)。結論:西藏拉薩地區臨床結覈分枝桿菌耐藥情況較為嚴重,應加彊臨床結覈分枝桿菌耐藥性鑑測,指導臨床用藥以防控耐藥菌的產生。
목적:료해랍살지구결핵분지간균대항결핵약물적내약정황,위림상합리용약제공삼고의거。방법:채용WHO추천적비례법대분리자서장랍살지구폐결핵환자적198주결핵분지간균진행4충항결핵약물(RFP、INH、SM、LVX)적약물민감성시험。결과:198주결핵분지간균중내약균주유125주,총내약솔위63.1%(125/198),총내다약솔위29.8%(59/198),초치내약솔위55.1%(64/116),복치내약솔위75.4%(40/53),초치내다약솔위20.7%(24/116),복치내다약솔위56.7%(30/53)。대RFP、INH、SM、LVX적내약솔분별위36.3%(72/198)、41.9%(83/198)、41.4%(82/198)화7.0%(14/198)。결론:서장랍살지구림상결핵분지간균내약정황교위엄중,응가강림상결핵분지간균내약성감측,지도림상용약이방공내약균적산생。
The drug resistance of the 198 isolated strains(Mycobacterium Tuberculosis)to four anti-TB drugs(Rifampin, Isoniazid, Streptomycin, Levofloxacin) were tested by using ratio method recommended by WHO forthe understanding drug-resistance of Mycobacterium Tuberculosis in Lhasa and for providing a theoretical basisfor the clinical medication. 125 strains of total 198 strains of Mycobacterium Tuberculosis were found to be resis-tant to the drugs with total drug-resistance rate of 63.1% and 29.8% of drug resistant strains were multi-drug re-sistant. The drug-resistance rates for initial TB patients and retreatment TB patients were 55.1% and 75.4% re-spectively. The multi-drug resistant rate for initial TB patients was 20.7% and 56.7% for retreatment TB pa-tients. The resistant rates of Mycobacterium Tuberculosis to RFP, INH, SM, LVX were 36.3%, 41.9%, 41.4% and7.0% respectively. The drug-resistant situation of clinical Mycobacterium Tuberculosis is more serious in Lhasaarea. Therefore, the monitoring drug resistance of clinical Mycobacterium Tuberculosis should be strengthenedand clinical medicine should be advised for preventing and controlling the generation of drug-resistant strains.